Vivek Garipalli compensation by year
Clover Health Investments Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $0 |
| Bonus | $0 |
| Stock awards | $389,569,439 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $389,569,439 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Clover Health Investments, Corp. DEF 14A filed April 26, 2023, accession 0001801170-23-000031, and prior-year filings.
How this page was built: the Clover Health Investments, Corp. filed document, accession 0001801170-23-000031. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 13,370,793 | $12,434,837 | — |
| PSU | 7,164,581 | $6,663,060 | — |
| PSU | 5,571,164 | $5,181,183 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Clover Health Investments, Corp.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
24 Form 4 lines since the FY2021 proxy (filed April 26, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-07 | Exercise or conversion derivative | — | 1,655,949 | — | 8,591,093 |
| 2026-01-07 | Exercise or conversion | — | 1,655,949 | $0.00 | 3,512,196 |
| 2026-01-07 | Exercise or conversion derivative | — | 3,342,699 | — | 10,247,042 |
| 2026-01-07 | Tax withholding | — | 1,655,949 | $2.59 | 1,856,247 |
| 2026-01-07 | Exercise or conversion derivative | — | 3,342,699 | — | 0 |
| 2025-08-08 | Purchase | — | 31,980 | $2.17 | 1,856,247 |
| 2025-08-07 | Purchase | — | 415,000 | $2.24 | 1,824,267 |
| 2025-01-07 | Exercise or conversion | — | 1,670,965 | $0.00 | 3,080,232 |
The 8 most recent of 24 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Clover Health Investments’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Vivek Garipalli · this page | Chief Executive Officer | $389,569,439 |
| Andrew Toy | President | $141,987,507 |
| Jamie Reynoso | Chief Operating Officer | $3,048,484 |
| Prabhdeep Singh | Chief Growth Officer | $2,679,325 |
| Mark Herbers | Interim Chief Financial Officer | $1,034,886 |
| Joseph Wagner | Former Chief Financial Officer | $407,342 |
Board service
Clover Health Investments board · FY2022–FY2025How this board is paid
Company policy: Clover Health Investments pays directors a $50,000 cash retainer and $200,000 in RSUs. As stated in Clover Health Investments's FY2025 proxy.
The full Clover Health Investments compensation record
free company briefThis page is one person within Clover Health Investments's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Clover Health Investments proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Clover Health Investments's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.